Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Test Link
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Special Reports
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Google
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Special Reports
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Google
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Test Link
Brought to you by:
Eli Lilly
Biotech
Why other Big Pharmas could follow Lilly into psychedelics
Industry experts told Fierce that Eli Lilly's $2.8 billion acquisition of AtaiBeckley should give the psychedelics space added momentum.
Will Maddox
,
Darren Incorvaia
Jul 20, 2026 4:00am
Lilly inks $2.8B AtaiBeckley psychedelic buyout to challenge J&J
Jul 16, 2026 7:32am
Insulet hires Convatec, Eli Lilly alum as new R&D chief
Jun 24, 2026 7:57am
Eli Lilly reunites with Abbisko in $1.9B, multitarget R&D pact
Jun 24, 2026 7:47am
Sangamo enters bankruptcy, reveals asset sales with 2 pharmas
Jun 23, 2026 10:57am
Fierce Pharma
Obesity meds, China drive $2T in projected 2032 drug sales: report
Jun 23, 2026 9:00am
